Immutep : Annual General Meeting CEO Presentation

Notice: Forward Looking Statements

The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Immutep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immutep's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immutep's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

Additionally, the INSIGHT investigator sponsored clinical trial described in this presentation is controlled by the lead investigator and therefore Immutep has no control over this clinical trial. This presentation should not be relied on as a recommendation or forecast by Immutep. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

2018 Summary

• • Strong operational and financial progress

• • Continued focus on LAG-3 immunotherapy

• • Progressed the development of four LAG-3 based product candidates for cancer and auto immune disease

• • Reported encouraging interim data for lead product candidate, IMP321 ('efti') from TACTI-mel trial

Ticker	ASX: IMM; NASDAQ: IMMP
Ordinary Shares / ADR	71% / 29%
Market Cap (12 Nov 18)	A$136M
Securities on Issue (12 Nov 18)	3.1 billion ordinary shares 8.8 million issued ADRs 1 ADR equals 100 ordinary shares

• • Committed partnerships with five of the world's largest pharmaceutical companies - Merck (MSD), Novartis and GSK, plus Merck (Germany) and Pfizer, along with Eddingpharm (EOC) in China

Highlights of past 12 months

Corporate

• • Name change to Immutep to reflect new focus on LAG-3 immunotherapeutics

• • Sound financial management

• • ASX Placement and SPP raising A$13.16 million

• • R&D cash rebates received from Australian & French schemes

• • Presentations at SITC, World Immunotherapy Congress, ASCO, Cambridge Healthcare Institutes I-O Summit, Immuno-Oncology Congress conferences

• • Board changes

• • 4 new patents granted

Highlights of past 12 months

R&D

• • TACTI-mel Phase I expanded to a fourth cohort due to encouraging interim data & positive safety review

• • Additional AIPAC Phase IIb clinical sites opened and commenced treating patients for randomised phase, recruitment of 160 patients (Nov 16, 2018)

• • IND application submitted with FDA granted

• • TACTI-002 Phase II trial preparations (trial protocol, selecting clinical sites)

• • INSIGHT (Investigator Initiated Trial study) recruiting patients, Frankfurt, Germany

• • Pre-clinical study successfully completed (IMP761)